Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis

Fibroblast growth factor (FGF)19, an endocrine hormone produced in the gut, acts in the liver to control bile acid synthesis. NGM282, an engineered FGF19 analog, is currently in clinical development for treating nonalcoholic steatohepatitis. However, the molecular mechanisms that integrate FGF19 wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Mei, Learned, R. Marc, Rossi, Stephen J., Tian, Hui, DePaoli, Alex M., Ling, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Biochemistry and Molecular Biology 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399511/
https://www.ncbi.nlm.nih.gov/pubmed/30679232
http://dx.doi.org/10.1194/jlr.M089961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399511/
https://www.ncbi.nlm.nih.gov/pubmed/30679232
http://dx.doi.org/10.1194/jlr.M089961

Ejemplares similares